[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@ArndtVogel](/creator/twitter/ArndtVogel)
"PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: XXXX vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial but rechallenge is an option in 4L @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979545038720753686) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T13:48Z 8829 followers, 4852 engagements


"CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs XX mo 👉 DFS: XX vs XX mo 👉 MPR: XX vs X% 🧐Very promising results neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca"  
[X Link](https://x.com/ArndtVogel/status/1979850194520047944) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T10:00Z 8829 followers, 9619 engagements


"TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs vs XX mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo @EASLedu @ILCAnews"  
[X Link](https://x.com/ArndtVogel/status/1980200970685481008) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:14Z 8829 followers, 3359 engagements


"PRODIGE 81/FFCD 2101 - TRIPLET HCC: Adding IPI to ATEZO + BEV in 1L uHCC #ESMO25 #ESMOAmbassadors 👉ORR: XX vs XXXX% 👉mPFS: XXX vs XXX mo 👉mOS: CC vs XX mo 🧐No benefit for adding IPI surprisingly clear negative.not enough anti-CTL4 @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979479438774452412) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T09:27Z 8816 followers, 6157 engagements


"IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II: Durvalumab plus tremelimumab in advanced BTC after failure of platinum-based CTx #ESMO25 #ESMOAmbassadors 👉 ICI is now SOC in 1L no convincing single for dual ICI in 2L but there are some ICI responder 👉we need biomarkers @myESMO"  
[X Link](https://x.com/ArndtVogel/status/1980202790564868298) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:21Z 8811 followers, 1996 engagements


"MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: XX% MPR: XX% any: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 🧐OS improved independent of TAP better in responders new SOC @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979158577697747093) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-17T12:12Z 8829 followers, 15.5K engagements


"PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: XX (-) vs XX% (+) 🧐Very innovative trail design ctDNA guided ACT is the future @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979531991625367833) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T12:56Z 8829 followers, 10.9K engagements


"Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next 🧐 Amazing efficacy for ICI in MSI CRC @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979536022305468468) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T13:12Z 8829 followers, 5208 engagements


"HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: XX% DCR XX% 👉 6mo PFS rate: XX% 👉 manageable safety 🧐 KRASi are the future in 1L @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979954921983394196) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T16:56Z 8829 followers, 5242 engagements


"Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: X vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC more trials to come. @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980204184827031608) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:27Z 8829 followers, 6096 engagements


"CASSANDRA phs 3: short vs long-course pre-operative CTx for stage I-III PDAC #ESMO25 #ESMOAmbassadors 👉 No difference in EFS between short vs long pre-OP CTx 👉but high CA19.9 response N0 resection dose intensity 🧐the jury is still out for best neoadjuvant approach @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980206290300481756) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:35Z 8829 followers, 4334 engagements


"🔥Presidential Session🔥 AGITG DYNAMIC-III trial : ctDNA-guided adjuvant CTx de-escalation in stage III CRC analysis of the ctDNA-cohort #ESMO25 #ESMOAmbassadors 👉 markedly reduced oxaliplatin exposure 👉 non-inferiority not shown specifically in high risk pts 👉 ctDNA burden prognostic 🧐feasible but not yet there.predictive uncertainty @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980291243868344735) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T15:13Z 8829 followers, 4318 engagements


"🔥Presidential Session🔥 FORTITUDE-101 phase III: Bemarituzumab plus CTx for advanced FGFR2b+ G/GEJC #ESMO25 #ESMOAmbassadors 👉mOS:17.9 vs XXXX mo but less benefit w/ follow up 👉Ocular AEs may be a concern 🧐Positive trial but not practice changing 👏great discussion by @YJanjigianMD @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980306502188474585) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T16:13Z 8829 followers, 7207 engagements